Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß signaling disorders, has announced its upcoming participation in the Guggenheim Healthcare Innovation Conference. Chair and CEO Jasbir S. Seehra, Ph.D., will engage in a fireside chat presentation on November 13, 2024, at 3:30 p.m. Eastern time.
The presentation will be accessible via live audio webcast, with an archived version available on the company's investor relations website for 90 days after the event.
Keros Therapeutics (Nasdaq: KROS), un'azienda biofarmaceutica in fase clinica specializzata nei disturbi della segnalazione TGF-ß, ha annunciato la sua prossima partecipazione alla Guggenheim Healthcare Innovation Conference. Il presidente e CEO Jasbir S. Seehra, Ph.D., parteciperà a una presentazione in stile conversazione informale il 13 novembre 2024, alle 15:30 ora orientale.
La presentazione sarà accessibile tramite un webcast audio in diretta, e una versione archiviata sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda per 90 giorni dopo l'evento.
Keros Therapeutics (Nasdaq: KROS), una compañía biofarmacéutica en etapa clínica especializada en trastornos de señalización TGF-ß, ha anunciado su próxima participación en la Guggenheim Healthcare Innovation Conference. El presidente y CEO Jasbir S. Seehra, Ph.D., realizará una presentación en formato de charla amena el 13 de noviembre de 2024, a las 3:30 p.m. hora del este.
La presentación estará disponible a través de un webcast de audio en vivo, y una versión archivada estará disponible en el sitio web de relaciones con inversores de la empresa durante 90 días después del evento.
Keros Therapeutics (Nasdaq: KROS) 는 TGF-ß 신호 장애를 전문으로 하는 임상 단계의 생물 의약품 회사로, 구겐하임 의료 혁신 회의에 참여할 예정이라고 발표했습니다. 의장 겸 CEO Jasbir S. Seehra, Ph.D.는 2024년 11월 13일 오후 3시 30분 동부 표준시 기준으로 진행되는 친밀한 대화 형식의 발표에 참여할 것입니다.
이 발표는 실시간 오디오 웨비나를 통해 접근할 수 있으며, 사건 후 90일 동안 회사의 투자자 관계 웹사이트에서 아카이브 버전을 이용할 수 있습니다.
Keros Therapeutics (Nasdaq: KROS), une entreprise biopharmaceutique en phase clinique spécialisée dans les troubles de la signalisation TGF-ß, a annoncé sa prochaine participation à la Guggenheim Healthcare Innovation Conference. Le président et PDG Jasbir S. Seehra, Ph.D., participera à une présentation de type discussion informelle le 13 novembre 2024 à 15h30, heure de l'Est.
La présentation sera accessible via un webcast audio en direct, et une version archivée sera disponible sur le site web des relations avec les investisseurs de l'entreprise pendant 90 jours après l'événement.
Keros Therapeutics (Nasdaq: KROS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das auf TGF-ß-Signalstörungen spezialisiert ist, hat seine bevorstehende Teilnahme an der Guggenheim Healthcare Innovation Conference bekannt gegeben. Vorsitzender und CEO Jasbir S. Seehra, Ph.D., wird am 13. November 2024 um 15:30 Uhr Eastern Time an einer lockeren Gesprächsveranstaltung teilnehmen.
Die Präsentation wird über einen Live-Audio-Webcast zugänglich sein, und eine archivierte Version wird für 90 Tage nach der Veranstaltung auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Guggenheim Healthcare Innovation Conference on Wednesday, November 13, 2024 at 3:30 p.m. Eastern time.
A live audio webcast of the fireside chat presentation will be available at https://wsw.com/webcast/guggen/kros/1967811 and an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of the event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. Keros’ lead product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis. Keros’ second product candidate, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ third product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
FAQ
When is Keros Therapeutics (KROS) presenting at the Guggenheim Healthcare Innovation Conference 2024?
How can I watch Keros Therapeutics (KROS) Guggenheim Conference presentation?
What is the main focus of Keros Therapeutics (KROS) research?
